Drug Database
Back to search

Poland· PL-100463764

Alvesco 160

A ciclesonide product containing ciclesonidum, registered in Poland by InPharm Sp. z o.o.. The same ATC class is registered in 15 of our 19 countries.

ATC R03BA08

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAlvesco 160ATCR03BA08REGISTER NO.PL-100463764PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ciclesonidumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ciclesonide is registered in 15 of 19 countries.

Countries holding a registration under ATC R03BA08 (ciclesonide), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search ciclesonide products by name

Ciclesonide · ATC R03BA08

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Ciclesonidum
Manufacturer
InPharm Sp. z o.o.
Country
Poland (PL)
ATC code
R03BA08
ATC class
Ciclesonide
Defined daily dose
0.16 mg, Inhal
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991475116

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

77 interactions on record for ciclesonide.

Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ciclesonide against other medicinesHow interaction checks work

Ciclesonide · interactions on record

77 records

  • 5 severe
  • 42 moderate
  • 19 minor
  • 11 info

Most severe, free to view

  • DesmopressinH01BA02severe
  • CladribineL01BB04severe
  • Dinutuximab betaL01FX06severe
  • Brexucabtagene autoleucelL01XL06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ciclesonide in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ciclesonide products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Alvesco, Ciclesonid Genetic
  • Bulgaria · Alvesco, Алвеско
  • Cyprus · Alvesco
  • Czechia · Alvesco, Ciclesonide Glenmark
  • Germany · Alvesco, Ciclesonid Glenmark
  • Denmark · Alvesco, Ciclasonide Glenmark
  • Spain · Alvesco
  • Finland · Alvesco, Ciclesonide Glenmark
  • France · Alvesco
  • United Kingdom (Northern Ireland) · Alvesco, Ciclesonide Advanz Pharma
  • Greece · Alvesco, Ciclair
  • Croatia · Airclesio, Alvesco
  • Hungary · Alvesco, Ciclesonid Sandoz
  • Ireland · Alvesco
  • Italy · Airven, Alvesco
  • Latvia · Alvesco
  • Netherlands · Alvesco Inhalator, Ciclesonide Ace
  • Norway · Alvesco, Ciclesonide Glenmark
  • Romania · Alvesco Inhaler
  • Sweden · Alvesco, Ciclesonide Glenmark
  • Slovenia · Alvesco, Cmykle
  • Slovakia · Airclesio, Alvesco

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/1872e906-32e2-4ef3-a01b-ced9225335f0
GET /v1/drugs/1872e906-32e2-4ef3-a01b-ced9225335f0?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Aerozol inhalacyjny, roztwór",
  "source": "urpl",
  "strength": "160 mcg/dawkę inh.",
  "packaging": "05909991475116 ¦ Rp ¦ 143580\n1 poj. 60 dawek",
  "substance": null,
  "common_name": "Ciclesonidum",
  "pl_product_id": "100463764",
  "pozwolenie_nr": "60/22",
  "auth_procedure": "IR",
  "authorisation_validity": "2027-01-31"
}
API referenceMCP serverPlans

See everything about ciclesonide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console